Praxbind ® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Praxbind ® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news